In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor

Journal of Vascular Surgery

Volumn 51, Issue 2, 2010, Pages 429-437

  Eefting, Daniel ^a   de Vries, Margreet R ^a   Grimbergen, Jos M ^a   Karper, Jacco C ^a   van Bockel, J Hajo ^a   Quax, Paul H A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL FRAGMENT OF UROKINASE; APOLIPOPROTEIN E3; COMPLEMENTARY DNA; LUCIFERASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; RECEPTOR BINDING; VASCULAR SMOOTH MUSCLE; VEIN GRAFT; VEIN GRAFT DISEASE;

ANIMALS; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; ELECTROPORATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT OCCLUSION, VASCULAR; GRAFT SURVIVAL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERPLASIA; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUTATION; PEPTIDE FRAGMENTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VENAE CAVAE;

EID: 75149133288     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.09.026     Document Type: Article

References (45)

1. Bulkley B.H., and Hutchins G.M. Accelerated "atherosclerosis." A morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation 55 (1977) 163-169
2. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
3. Conte M.S., Bandyk D.F., Clowes A.W., Moneta G.L., Seely L., Lorenz T.J., et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43 (2006) 742-751
4. Schwartz S.M. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 100 (1997) S87-S89
5. Hu Y., Mayr M., Metzler B., Erdel M., Davison F., and Xu Q. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res 91 (2002) e13-e20
6. Hilker M., Buerke M., Lehr H.A., Oelert H., and Hake U. Bypass graft disease: analysis of proliferative activity in human aorto-coronary bypass grafts. Heart Surg Forum 5 (2002) S331-S341
7. Davies M.G., and Hagen P.O. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 9 (1995) 7-18
8. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86 (2001) 324-333
9. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
10. van Hinsbergh V.W., Engelse M.A., and Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26 (2006) 716-728
11. Newby A.C., Southgate K.M., and Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 89 suppl 1 (1994) 59-70
12. Southgate K.M., Mehta D., Izzat M.B., Newby A.C., and Angelini G.D. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 19 (1999) 1640-1649
13. Newby A.C., and George S.J. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr Opin Cardiol 11 (1996) 574-582
14. Pasterkamp G., Schoneveld A.H., Hijnen D.J., de Kleijn D.P., Teepen H., van der Wal A.C., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
15. Forough R., Koyama N., Hasenstab D., Lea H., Clowes M., Nikkari S.T., et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vitro. Circ Res 79 (1996) 812-820
16. George S.J., Johnson J.L., Angelini G.D., Newby A.C., and Baker A.H. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 9 (1998) 867-877
17. George S.J., Baker A.H., Angelini G.D., and Newby A.C. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 5 (1998) 1552-1560
18. George S.J., Lloyd C.T., Angelini G.D., Newby A.C., and Baker A.H. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101 (2000) 296-304
19. Garcia-Touchard A., Henry T.D., Sangiorgi G., Spagnoli L.G., Mauriello A., Conover C., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 25 (2005) 1119-1127
20. Lamfers M.L., Grimbergen J.M., Aalders M.C., Havenga M.J., de Vries M.R., Huisman L.G., et al. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res 91 (2002) 945-952
21. Zou Y., Dietrich H., Hu Y., Metzler B., Wick G., and Xu Q. Mouse model of venous bypass graft arteriosclerosis. Am J Pathol 153 (1998) 1301-1310
22. Lardenoye J.H., de Vries M.R., Lowik C.W., Xu Q., Dhore C.R., Cleutjens J.P., et al. Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice. Circ Res 91 (2002) 577-584
23. Sluijter J.P., de Kleijn D.P., and Pasterkamp G. Vascular remodeling and protease inhibition-bench to bedside. Cardiovasc Res 69 (2006) 595-603
24. Eefting D., Grimbergen J.M., de Vries M.R., van Weel V., Kaijzel E.L., Que I., et al. Prolonged in vitro gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. Hum Gene Ther 18 (2007) 861-869
25. Andre F., and Mir L.M. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 11 (2004) S33-S42
26. Quax P.H., Grimbergen J.M., Lansink M., Bakker A.H., Blatter M.C., Belin D., et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler Thromb Vasc Biol 18 (1998) 693-701
27. van den Maagdenberg A.M., Hofker M.H., Krimpenfort P.J., de Bruijn I., van Vlijmen B., van der Boom H., et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 268 (1993) 10540-10545
28. van Vlijmen B.J., van den Maagdenberg A.M., Gijbels M.J., van der Boom H., HogenEsch H., Frants R.R., et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93 (1994) 1403-1410
29. Eefting D., Schepers A., de Vries M.R., Pires N.M., Grimbergen J.M., Lagerweij T., et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis 193 (2007) 335-342
30. McMahon J.M., Signori E., Wells K.E., Fazio V.M., and Wells D.J. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase-increased expression with reduced muscle damage. Gene Ther 8 (2001) 1264-1270
31. Lardenoye J.H., de Vries M.R., Grimbergen J.M., Havekes L.M., Knaapen M.W., Kockx M.M., et al. Inhibition of accelerated atherosclerosis in vein grafts by placement of external stent in apoE*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 22 (2002) 1433-1438
32. Koolwijk P., van Erck M.G., de Vree W.J., Vermeer M.A., Weich H.A., Hanemaaijer R., et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 132 (1996) 1177-1188
33. Kranzhofer A., Baker A.H., George S.J., and Newby A.C. Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein. Arterioscler Thromb Vasc Biol 19 (1999) 255-265
34. Christiansen J.F., Hartwig D., Bechtel J.F., Kluter H., Sievers H., Schonbeck U., et al. Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries. Ann Thorac Surg 77 (2004) 1575-1579
35. Hu Y., Baker A.H., Zou Y., Newby A.C., and Xu Q. Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 21 (2001) 1275-1280
36. Puhakka H.L., Turunen P., Rutanen J., Hiltunen M.O., Turunen M.P., and Yla-Herttuala S. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res 42 (2005) 361-367
37. Puhakka H.L., Turunen P., Gruchala M., Bursill C., Heikura T., Vajanto I., et al. Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. In vitro 19 (2005) 515-521
38. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Béthune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 (2003) 8263-8271
39. Havenga M.J., Lemckert A.A., Grimbergen J.M., Vogels R., Huisman L.G., Valerio D., et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75 (2001) 3335-3342
40. Quax P.H., Lamfers M.L., Lardenoye J.H., Grimbergen J.M., de Vries M.R., Slomp J., et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 103 (2001) 562-569
41. Libby P., and Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8 (2002) 1257-1262
42. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
43. Mott J.D., and Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16 (2004) 558-564
44. Estreicher A., Muhlhauser J., Carpentier J.L., Orci L., and Vassalli J.D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111 (1990) 783-792
45. Matías-Román S., Gálvez B.G., Genís L., Yáñez-Mó M., de la Rosa G., Sánchez-Mateos P., et al. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 105 (2005) 3956-3964